JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, acquired Syracuse Biopharma (Hong Kong) Limited, which includes the license for Eureka Therapeutics’ ARTEMIS® antibody TCR and solid tumor technology for exclusive use in China and the ASEAN countries.
The terms of the deal were not disclosed.
Dr. Cheng Liu, Founder and President of Eureka Therapeutics, will join the Board of Directors of JW Therapeutics, and Victor Shum, Chief Business Officer and General Counsel of Eureka, will join as a Board Observer.
Founded in February 2016 in Shanghai and led by Dr. James Li, CEO, JW Therapeutics is a clinical-stage biopharmaceutical company focusing on the development, transformation and promotion of cell immunotherapy. The company has obtained approval for the clinical trials of CAR-T product targeting CD19.
Formed in 2017 by Eureka Therapeutics to commercialize its proprietary TCR-mimic and antibody-TCR ARTEMIS® programs in China and the ASEAN countries, Syracuse Biopharma provides clinical programs that include its anti-AFP ARTEMIS® program for the treatment of hepatocellular carcinoma (HCC), the predominant type of liver cancer, which is currently in a Phase I/II clinical trial in the United States.